Bayer AG

Discover Bayer AG’s early‑stage prostate‑cancer therapy showing 18% response & 9.6‑month PFS, plus a promising PSMA‑radionuclide trial, amid volatile finances and future FDA/EMA plans.

Explore how Bayer’s lawsuits over Nubeqa vs. Erleada and glyphosate reshape its pharma and crop‑science futures, affecting pricing, regulation, and stock value.

Shares of Bayer AG fall 3.8 % amid earnings cuts and regulatory delays, yet its diverse pharma, diagnostics and agro‑chemical portfolio still underpins long‑term growth and clinical gains.

Discover how Bayer’s $7.25 billion glyphosate settlement could stabilize earnings, boost investor confidence, and influence healthcare risk‑management.

Explore how Bayer AG’s Roundup settlement, Fitch downgrade, and market shifts risk its future pharma and ag‑chem success.

Read how Bayer’s $7.25 billion Roundup settlement and U.S. special status shift investor sentiment, legal risk, and future product pricing.

Discover how Bayer’s multi‑billion‑dollar Roundup settlement reshapes its legal risk, finances, and pharma‑agri strategy—and what it means for investors.

Discover how Bayer’s new anticoagulant Asundexian could cut stroke rates, improve patient adherence, and reshape its portfolio in the competitive NOAC market.

Explore Bayer’s 2026 market outlook: modest price dip, R&D focus on kinase inhibitors, IL‑23 therapy, and CRISPR crop tech, plus investor signals for future gains.

Discover how Bayer AG’s stock surge is driven by a potential glyphosate ruling, patent cliffs, and strategic moves in pharma, biotech, and diagnostics.